Previous 10 | Next 10 |
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Podcast listener? Subscribe now to receive Wall Street Breakfast by 8:00 a.m. every t...
Based on feedback from the FDA and the receipt of the minutes from its meeting with the agency, Nabriva Therapeutics (NASDAQ: NBRV ) expects to resubmit its marketing application next quarter for CONTEPO (fosfomycin) for the treatment of complicated urinary tract infections, including acut...
DUBLIN, Ireland, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that following its receipt of final Type A Meeti...
Paratek Pharmaceuticals ( PRTK ) reported earnings on Tuesday, August 6, with the stock trading up over 30% in response to the report and then running further throughout the rest of the week. I find the numbers from the launch of Nuzyra (omadacycline), however, to be less than encouraging. I...
Nabriva Therapeutics (NASDAQ: NBRV ): Q2 GAAP EPS of -$0.44. More news on: Nabriva Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three and six months ended June 3...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Chief Commercial Officer Francesc...
WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...
WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...
News, Short Squeeze, Breakout and More Instantly...
Nabriva Therapeutics plc Company Name:
NBRV Stock Symbol:
NASDAQ Market:
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...